Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration

Journal of Medicine

Volumn 31, Issue 5-6, 2000, Pages 278-282

  Ambrus, J L ^a   Toumbis, C A ^b   Karakousis, C P ^a   Kulaylat, M ^a   Akhter, S ^a   Plavsic, L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Human malignant melanoma; Pentoxifylline; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; PENTOXIFYLLINE; THALIDOMIDE;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORNEA NEOVASCULARIZATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; MACACA; MELANOMA CELL; NEOPLASM; NONHUMAN; RETINA MACULA DEGENERATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CORNEA; CORNEAL NEOVASCULARIZATION; DRUG COMBINATIONS; ENZYME INHIBITORS; HUMANS; KERATINOCYTES; MACACA; MACULAR DEGENERATION; MELANOMA; PENTOXIFYLLINE; THALIDOMIDE;

EID: 0034447850     PISSN: 00257850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ambrus, J.L., Ambrus, C.M., Toumbis, C.A., Forgach, P., Karakousis, C.P., Niswander, P., and Lane, W. (1991): Studies on tumor induced angiogenesis. J. Med. 22: 355-369.
2. Ambrus, J.L., Ambrus, C.M., Toumbis, C.A., Forgach, P., Karakousis, C.P. and Niswander, P. (1992): Tumor induced angiogenesis. Effect of platelet derived growth factor (PDGF), pentoxifylline, sodium diethyldithiocarbamate, epsilon amino caproic acid and transaxemic acid. In: Angiogenesis in Health and Disease. Edited by Maragoudakis, ME. pp 185-194.
3. Ambrus, J.L., Ambrus, C.M., Forgach, P., Stadler, S., Halpern, J., Sayyid, S., Niswander, P. and Toumbis, C.A. (1992a): Studies on tumor induced angiogenesis. In: Angiogenesis: Key Principles: Science-Technology-Medicine. Edited by R. Steiner, PB Weisz, R. Langer. Birkhauser Verlag Basel/Switzerland. pp 436-444.
4. Folkman, J. (1974): Tumor angiogenesis. Advan. Cancer Res. 19: 331-358.
5. Folkman, J. (1975): Tumor angiogenesis. In: Biology of Tumors. Edited by Becker, F.F. Plenum Press. New York. pp 355-388.
6. Gullino, P. (1978): Angiogenesis and oncogenesis. J. Nat. Cancer Inst. 61: 639-643.
7. Gullino, P. (1981): Angiogenesis factor(s). In: Tissue Growth Factors. Edited by Baserga, R., Springer-Verlag. New York. pp. 428-449.
8. Jakob, W., Jentzsch, K., Mauersberger, B. and Heder, G. (1978): The chick embryo chorioallantoic membrane as a bioassay for angiogenesis factors: reactions induced by carried materials. Exp. Pathol. 15: 241-249.
9. Jakob, W., Jentzsch, K., Mauersberger, B. and Oehme, P. (1977): Demonstration of angiogenesis activity in the corpus luteum of cattle. Exp. Pathol. 13: 231-236.
10. Klinworth, G. (1991): Corneal Angiogenesis: A Comprehensive Critical Review. Springer Verlag. New York.
11. Langer, R. and Folkman, J. (1981): Angiogenesis inhibitors. In: Molecular Actions and Targets for Cancer Chemotherapy Agents. Edited by Sartorelli, A., Lazo, J., Bertino, J. Academic Press. New York. pp 511-525.
12. Marwick, C. (1997): Thalidomide back-under strict control. JAMA 278: 1135-1137.
13. Phillips, P. and Kumar, S. (1979): Tumor angiogenesis factor (TAF) and its neutralization by a xenogeneic antiserum. Int. J. Cancer 23: 82-88.
14. Tseng, S., Pak G., Washenik, K., Pomeranz, M. and Shupack J. (1996): Rediscovering thalidomide: a review of its mechanism of action side effects, and potential uses. J. Am. Acad. Dermatol 35: 969-979.